55. 再発性多発軟骨炎 Relapsing polychondritis Clinical trials / Disease details
臨床試験数 : 7 / 薬物数 : 10 - (DrugBank : 9) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 100
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-003964-30-GB (EUCTR) | 22/10/2020 | 31/07/2020 | Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory vasculitis in adults and children. | Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory primary non-ANCA associated vasculitis in adults and children - Biologics in refractory vasculitis (BIOVAS) | Non-ANCA associated vasculitides: 1.Giant cell arteritis (GCA)2.Takayasu’s arteritis (TA)3.Polyarteritis nodosa (PAN) or cutaneous polyarteritis unrelated to hepatitis B (CPAN)4.Relapsing polychondritis (RP)5.IgA vasculitis (IgAV)6.Cogan’s syndrome7.Non-infective cryoglobulinaemia8.Primary angiitis of central nervous system (PACNS) MedDRA version: 21.1;Level: PT;Classification code 10047115;Term: Vasculitis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Infliximab Product Code: N/A INN or Proposed INN: Infliximab Trade Name: Rituximab Product Name: Rituximab INN or Proposed INN: Rituximab Trade Name: Tocilizumab Product Name: Tocilizumab Product Code: N/A INN or Proposed INN: Tocilizumab | Cambridge University Hospitals NHS Foundation Trust | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 140 | Phase 2 | United Kingdom | ||
| 2 | NCT01104480 (ClinicalTrials.gov) | May 2010 | 13/4/2010 | Tocilizumab for Relapsing Polychondritis | Efficacy of Tocilizumab in a Patient With Relapsing Polychondritis | Relapsing Polychondritis | Drug: Tocilizumab | McMaster Children's Hospital | NULL | Withdrawn | 12 Years | 15 Years | Male | 0 | Phase 2 | Canada |
| 3 | NCT01041248 (ClinicalTrials.gov) | January 2010 | 30/12/2009 | Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab | Efficacy of Tocilizumab in a Patient With Relapsing Polychondritis | Relapsing Polychondritis | Drug: Tocilizumab | Children's Hospital of Eastern Ontario | NULL | Completed | N/A | N/A | Male | 1 | N/A | Canada |